All In Biotech

BLA 125147 · Amgen

Vectibix

Panitumumab · Iv (Infusion) · Epidermal Growth Factor Receptor Antagonist

NovelAccelerated approval

Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Sep 27, 2006

Approved uses

6

Original approval plus efficacy supplements

Registered trials

282

32 Phase 3, 41 recruiting

FAERS reports

16,106

14,116 serious, 2,738 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DERMATOLOGIC TOXICITY Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC Grade 3 and higher) in 15% of patients receiving Vectibix monotherapy [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . WARNING: DERMATOLOGIC TOXICITY See full prescribing information for complete boxed warning . Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving monotherapy. ( 2.3 , 5.1 , 6.1 )

What it is approved for

From the label in effect Jun 23, 2026.

Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of: Adult patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test) Metastatic Colorectal Cancer (mCRC)*: In combination with FOLFOX for first-line treatment. ( 1 , 14.2 ) As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. ( 1 , 14.1 ) KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC)* In combination with sotorasib, for the treatment of adult patients with KRAS G12C- mutated mCRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1 ) *Limitations of Use: Vectibix is not indicated for the treatment of patients with RAS -mutant mCRC unless used in combination with sotorasib in KRAS G12C-mutated mCRC. Vectibix is not indicated for the treatment of patients with mCRC for whom RAS mutation status is unknown ( 1 , 2.1 , 5.2 , 12.1 , 14.3 ). Metastatic Colorectal Cancer (mCRC) RAS Wild-Type mCRC Vectibix is indicated for the treatment of adult patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test) metastatic colorectal cancer (mCRC) [see Dosage and Administration (2.1) ] : As first-line therapy in combination with FOLFOX [see Clinical Studies (14.2) ] . As monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy [see Clinical Studies (14.1) ] . KRAS G12C -mutated mCRC Vectibix, in combination with sotorasib, is indicated for the treatment of adult patients with KRAS G12C- mutated mCRC, as determined by...

Mechanism: The EGFR is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases, including EGFR, HER2, HER3, and HER4. EGFR is constitutively expressed in normal epithelial tissues, including the skin and hair follicle. EGFR is overexpressed in certain human cancers, including colon and rectum cancers. Interaction of EGFR with its normal ligands (e.g., EGF, transforming growth factor-alpha) leads to phosphorylation and activation of a series of intracellular proteins, which in turn regulate transcription of genes involved with cellular growth and survival,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 16, 2025 Supplement 213 · Efficacy · priority review LabelLetter
  • Jun 29, 2017 Supplement 207 · Efficacy LabelLetter
  • May 23, 2014 Supplement 186 · Efficacy LabelLetter
  • May 23, 2014 Supplement 108 · Efficacy LabelLetter
  • Jun 23, 2008 Supplement 26 · Efficacy LetterLabel
  • Sep 27, 2006 Original approval · Type 1 - New Molecular Entity NovelAccelerated approvalLabelReviewLetter
3 products under this application
  • VECTIBIX · PANITUMUMAB 20ML/400MG · INJECTABLE, IV (INFUSION) · Prescription
  • VECTIBIX · PANITUMUMAB 5ML/100MG · INJECTABLE, IV (INFUSION) · Prescription
  • VECTIBIX · PANITUMUMAB 10ML/200MG · INJECTABLE, IV (INFUSION) · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Panitumumab" as an intervention, any sponsor and status, largest first.

All 282 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • rash1,979
  • diarrhoea1,649
  • dermatitis acneiform1,069
  • death1,060
  • neutropenia963
  • skin toxicity934
  • nausea863
  • colorectal cancer metastatic861
  • hypomagnesaemia849
  • disease progression749
  • neuropathy peripheral749
  • off label use743

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20053
200626
2007315
2008326
2009334
2010359
2011601
2012524
2013489
2014625
2015709
2016962
2017965
20181,176
20191,241
20201,015
2021891
2022956
20231,169
20241,050
2025948
20261,422

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vectibix (Panitumumab)

2024 spending

$4.2M

Beneficiaries

68

303 claims

Per beneficiary

$61,449

$328.72 per unit

View as table
YearSpending
2020$1,135,862
2021$2,235,138
2022$2,283,143
2023$3,629,418
2024$4,178,524

Part B: Vectibix (Panitumumab) · HCPCS J9303

2024 spending

$137M

Beneficiaries

2,636

18,403 claims

Per beneficiary

$51,946

2024 ASP limit $154.98 per unit

View as table
YearSpending
2020$100,556,796
2021$100,065,716
2022$118,238,478
2023$132,133,362
2024$136,930,119

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 398 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.